Form 4: Cue Biopharma CEO Receives Stock Grants

Cue Biopharma's CEO, Lin Shao-Lee, was granted restricted and performance stock units on July 9, 2026, as disclosed in a Form 4 filing.

Summary

• Lin Shao-Lee, CEO and Director of Cue Biopharma, Inc., received a grant of 327,537 shares of Common Stock on July 9, 2026.
• This grant includes restricted stock units (RSUs) that vest quarterly over 48 months, contingent on continued service.
• Additionally, performance stock units (PSUs) were granted, which are subject to stock-price based vesting conditions at $33.00, $38.50, and $44.00 per share for five consecutive trading days.
• If stock price targets are not met within 24 months of the grant date, the PSUs will be forfeited.
• Following these transactions, Lin Shao-Lee beneficially owns 655,074 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it details standard executive compensation practices and aligns management incentives with stock performance, but does not provide new operational or financial performance data.

Positives

• The CEO received a significant grant of stock units, indicating continued investment and commitment to the company's long-term success.
• The performance-based nature of the PSUs aligns management's incentives with shareholder value creation through stock price appreciation.

Negatives

• The vesting of PSUs is contingent on achieving specific stock price targets, which may not be met, leading to forfeiture.

Risks

• The performance stock units are subject to forfeiture if stock price targets are not met within 24 months from the grant date.
• Vesting of restricted stock units is contingent on the reporting person's continued service with the issuer.

Future Outlook

The future outlook for the stock price is tied to the achievement of specific stock-price based vesting conditions for the performance stock units, with targets set at $33.00, $38.50, and $44.00 per share.

Industry Context

StockSavvy.ai notes that grants of equity to key executives are common in the biopharmaceutical industry as a tool for attracting and retaining talent, and for aligning executive interests with those of shareholders, particularly in companies focused on long-term value creation through drug development.

Stakeholder Impact

• Shareholders: The alignment of executive compensation with stock price performance may positively influence long-term shareholder value.
• Employees: The CEO's continued service requirement for RSUs highlights the importance of employee retention for company operations.
• Management: The grants serve as a significant incentive for the CEO to drive company performance and stock appreciation.

Next Steps

• Continued service by Lin Shao-Lee to meet vesting requirements for RSUs.
• Achievement of specific stock price targets ($33.00, $38.50, $44.00) within 24 months for PSUs to vest.

Key Dates

Keywords

Cue Biopharma, CUE, Form 4, Stock Grant, RSU, PSU, Insider Transaction, Executive Compensation, Lin Shao-Lee